The recent developments of new carbonic anhydrase inhibitors have stimulated interest in the possibility of their use as ocular hypotensive agents. The clinical and experimental value of the carbonic anhydrase inhibitor acetazolamide in lowering intraocular pressure has already been proved.1-5 It follows that the newer agents might also have similar ocular pharmacologic action. Dichlorphenamide and chlorothiazide (Merck Sharp & Dohme) were chosen for experimental investigation in this study.
Dichlorphenamide is a dichlorinated benzenedisulfonamide. Its chemical name is 1,3-disulfamyl-4,5-dichlorobenzene. The drug is a weak dibasic acid and is said to be soluble in dilute solutions of sodium carbonate and sodium hydroxide, stable at room temperature. In vitro, dichlorphenamide has been reported as approximately 30 times as effective an inhibitor of carbonic anhydrase as acetazolamide and 300 times as effective as sulfanilamide.6 It has been found to increase sodium excretion of the kidney in dogs and also
SCHIMEK RA, BALIAN JV, LEPLEY FJ, OTTUM JA. Evaluation of Dichlorphenamide as an Ocular Hypotensive Agent. AMA Arch Ophthalmol. 1958;60(6):1053-1060. doi:10.1001/archopht.1958.00940081073011